Precigen, Inc.

NASDAQ:PGEN

Biotechnology

Healthcare
$4.27 -2.08%

-$0.10 today

Market cap
$1.53B
Beta
1.06
P/E (TTM)
-7.1
EPS (TTM)
-$0.65
52W Low $1.39High $5.47

Volume 4.27M

Average 4.72M

PGEN EBITDA Margin

EBITDA as a percentage of revenue.

Precigen, Inc.NASDAQ: PGEN

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 43.9%

EBITDA Margin was 43.9% in Q2 FY2026, up 3224.6 pp from a year earlier. On a trailing-twelve-month basis it was -167.8%, up 2670.7 pp year over year. Over 3 fiscal years it narrowed by 2283.2 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 52.6% for the fiscal year ending Dec 2026, up from -2515.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
43.9%+60.7 pp QoQ
Last fiscal yearDec 2025
-2515.2%+631.2 pp YoY
LTMJun 2026
-167.8%+2670.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3224.6 pp+5002.1 pp+1777.5 pp
1 year+631.2 pp+2567.8 pp+1936.6 pp
3 years-2283.2 pp+2594.3 pp+4877.5 pp
5 years+2593.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2515.2%
Year-over-year change
+631.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PGEN compares with its peers on the latest reported figures

  • PGEN's LTM Jun 2026 EBITDA Margin of -167.8% is the 3rd highest of the 7 companies compared; the peer median is -259.9%.
  • Its year-over-year change of +2670.7 pp is the highest of 6, against a peer median of -57.3 pp.
  • Over three fiscal years its change of -2283.2 pp compares with a peer median of +514.1 pp.
PGEN Competitors Peer median
EBITDA Margin for PGEN and competitors
Company Period LTM level YoY 3-year change
ABEOAbeona Therapeutics Inc.LTM Mar 2026505.0% —+3781.9 pp
DTILPrecision BioSciences, Inc.LTM Mar 2026-89.7% -57.3 pp+126.4 pp
PGENPrecigen, Inc.LTM Jun 2026-167.8% +2670.7 pp-2283.2 pp
EDITEditas Medicine, Inc.LTM Mar 2026-258.7% +387.8 pp+719.4 pp
RGNXREGENXBIO Inc.LTM Mar 2026-261.2% -183.0 pp+138.5 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-581.9% +549.6 pp+308.9 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-1917.5% -679.9 pp+127741.9 pp
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding PGEN) -259.9%-57.3 pp+514.1 pp

Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.27M26.91M6.23M3.93M9.68M
Cost of Revenue53.68M6.34M6.12M4.27M6.1M
Gross Profit(39.41M)20.57M106K(342K)3.59M
Gross Margin-276.2%76.4%1.7%-8.7%37.1%
Research & Development47.93M47.17M48.61M53.07M40.06M
Selling, General & Admin048.01M40.42M41.29M70.13M
Operating Expenses52.54M96.3M99.86M134.69M110.19M
Depreciation & Amortization13.76M10.77M6.67M4.53M3.2M
EBITDA(77.64M)(62.43M)(89.23M)(123.5M)(243.57M)
EBITDA Margin-544.2%-232.0%-1433.3%-3146.4%-2515.2%
Operating Income(91.95M)(75.73M)(99.76M)(135.03M)(106.6M)
Operating Margin-644.5%-281.4%-1602.5%-3440.2%-1100.8%
Interest Income171K133K3.24M1.42M3.22M
Interest Expense18.76M6.77M468K6K3.87M
Other Income / Expenses(19.02M)(4.24M)3.4M7M(144.04M)
Income Before Tax(110.97M)(79.97M)(96.36M)(128.03M)(250.64M)
Pre-Tax Margin-777.8%-297.2%-1548.0%-3261.9%-2588.2%
Income Tax Expense(160K)(189K)(458K)(1.79M)3K
Net Income(92.17M)28.32M(95.9M)(126.24M)(250.64M)
Net Margin-646.0%105.2%-1540.6%-3216.2%-2588.2%
EPS (Basic)(0.47)(0.33)(0.39)(0.47)(1.41)
EPS (Diluted)(0.47)(0.40)(0.39)(0.47)(1.41)
Weighted Avg Shares197.76M200.36M244.54M267.73M304.71M
Weighted Avg Shares (Diluted)197.76M200.36M244.54M267.73M304.71M

Precigen, Inc.

NASDAQ:PGEN

Intrinsic Alpha fair value

Locked

Current Price

$4.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.